CRISPR Therapeutics CRSP Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's free cash flow margin?
- CRISPR Therapeutics (CRSP) reported free cash flow margin of -9,777.6% in Q1 2026.
- How has CRISPR Therapeutics's free cash flow margin changed year-over-year?
- CRISPR Therapeutics's free cash flow margin decreased by 1096.6% year-over-year, from -817.1% to -9,777.6%.
- What is the long-term trend for CRISPR Therapeutics's free cash flow margin?
- Over 4 years (2020 to 2025), CRISPR Therapeutics's free cash flow margin has grown at a -27.5% compound annual growth rate (CAGR), from -35,705.7% to -9,855.5%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.